Abstract:We investigated the therapeutic potential of targeting integrin/FAK-dependent signaling, an adhesion receptor-mediated pathway that has been increasingly linked to non-small cell lung cancer (NSCLC) malignancy. Our analysis of the TCGA cohort showed that a subset of pro-tumorigenic integrins, including alpha 1 beta 1, alpha 2 beta 1, alpha 3 beta 1, alpha 5 beta 1, and alpha 6 beta 4, were frequently amplified or upregulated at the genomic or mRNA level in KRAS or EGFR mutation/overexpression-enriched adenocarcinomas. These alterations appeared complementary, correlated with poor patient survival (p< 0.0072), and were collaborative with KRAS mutation-coupled alpha v integrins (p< 0.00159). Since integrin/FAK-dependent signaling is tightly coupled with normal human physiology, we sought to use a synthetic lethal-type targeting comprising of VS-6063, a chemical inhibitor of integrin-mediated FAK activity, and A549 cells, which carry a KRAS mutation and EGFR overexpression. Our screening analysis revealed that JQ1 and IBET-762, inhibitors of epigenetic reader BRD4, and LBH589, a pan inhibitor of histone deacetylases (HDACs), exhibited synergy with VS-6063 in mitigating tumor cell viability. This epigenetic link was corroborated by strong effects of additional inhibitors and RNAi-mediated knockdown of FAK and BRD4 or its downstream effector, c-Myc. Low doses of JQ1 (<= 0.5 mu M) markedly escalated efficacy of VS-6063 across a panel of 10 NSCLC cell lines. This catalyst-like effect is in line with the oncogenic landscape in the TCGA cohort since c-Myc falls downstream of the KRAS and EGFR oncogenes. Mechanistically, co-inhibiting the integrin-FAK and BRD4/c-Myc axes synergistically induced apoptotic cell death and DNA damage response, and impaired stemness-associated tumorsphere formation. These effects were accompanied by a marked inhibition of Akt- and p130Cas/Src-dependent signaling, but not Erk1/2 activity. Meanwhile, JQ1 alone or in combination with VS-6063 attenuated cell-cell adhesion and extracellular matrix (ECM)-dependent cell spreading, which is reminiscent of phenotype induced by malfunctional E-cadherin or integrins. Paradoxically, this phenotypic impact coincided with downregulation of epithelial-mesenchymal transition (EMT)-inducting transcription factor ZEB1 or Snail. Finally, we showed that the effect of the VS-6063/JQ1 combination was nearly equivalent to that of VS-6063 plus Carboplatin or Osimertinib. Overall, our study indicates that the integrin/FAK and BRD4/c-Myc axes cooperatively drive NSCLC virulence, and a co-targeting may provide a line of therapy capable of overcoming EGFR/KRAS-driven malignancy.

Src heterodimerically activates Lyn or Fyn to serve as targets for the diagnosis and treatment of esophageal squamous cell carcinoma

Src SUMOylation Inhibits Tumor Growth Via Decreasing FAK Y925 Phosphorylation.

Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma

Inhibition Of Src Family Kinases Reduces Myeloid-Derived Suppressor Cells In Head And Neck Cancer

Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor.

Dysregulation of CXCL14 promotes malignant phenotypes of esophageal squamous carcinoma cells via regulating SRC and EGFR signaling

Co‐targeting FAK and Gli1 Inhibits the Tumor‐associated Macrophages‐released CCL22‐mediated Esophageal Squamous Cell Carcinoma Malignancy

Integrated proteomics and phosphoproteomics analyses of esophageal cancer cells with different invasive abilities

Abstract 5961: NRF2-responsive kinases in esophageal squamous cell carcinoma

Targeting the SOX2/CDP Protein Complex with a Peptide Suppresses the Malignant Progression of Esophageal Squamous Cell Carcinoma.

Epigenetic Input Dictates the Threshold of Targeting of the Integrin-Dependent Pathway in Non-small Cell Lung Cancer.

Overexpressed NEDD8 as a potential therapeutic target in esophageal squamous cell carcinoma

c-Src activation promotes nasopharyngeal carcinoma metastasis by inducing the epithelial-mesenchymal transition via PI3K/Akt signaling pathway: a new and promising target for NPC.

Suppressing SENP1 Inhibits Esophageal Squamous Carcinoma Cell Growth Via SIRT6 SUMOylation

Targeting HOX/PBX Dimer Formation As a Potential Therapeutic Option in Esophageal Squamous Cell Carcinoma.

Epigenetically upregulated oncoprotein PLCE1 drives esophageal carcinoma angiogenesis and proliferation via activating the PI-PLCε-NF-κB signaling pathway and VEGF-C/ Bcl-2 expression

LPCAT1 reprogramming cholesterol metabolism promotes the progression of esophageal squamous cell carcinoma

NR2F1-induced NR2F1-AS1 Promotes Esophageal Squamous Cell Carcinoma Progression Via Activating Hedgehog Signaling Pathway.

Focal adhesion kinase (FAK) inhibitor-defactinib suppresses the malignant progression of human esophageal squamous cell carcinoma (ESCC) cells via effective blockade of PI3K/AKT axis and downstream molecular network

A multi‐omics study delineates new molecular features and therapeutic targets for esophageal squamous cell carcinoma

Dasatinib Enhances Cisplatin Sensitivity in Human Esophageal Squamous Cell Carcinoma (ESCC) Cells Via Suppression of PI3K/AKT and Stat3 Pathways